Skip to main content
. 2020 Apr 10;18:71. doi: 10.1186/s12957-020-01848-1

Table 2.

Meta-analysis results of all available studies in measured outcomes

Measured outcomes Subgroup No. studies No. patients Heterogeneity test Model RR/WMD 95% CI P Begg’s test Egger’s test
I2(%) P Pr > |z|* Pr > |z|** P > |t|*
Preoperative cholangitis Total 9 813 vs. 622 19.1 0.273 Random 0.46 0.34, 0.62 < 0.001 0.404 0.466 0.73
HCC 2 145 vs. 53 81.5 0.02 Random 0.5 0.19, 1.3 0.156 -- -- --
DBO 4 535 vs. 439 17.4 0.259 Random 0.38 0.26, 0.57 < 0.001 0.174 0.308 0.282
Preoperative pancreatitis Total 7 750 vs. 508 0 0.929 Fixed 0.69 0.50, 0.95 0.023 0.881 1 0.551
HCC 2 145 vs. 53 0 0.999 Fixed 0.67 0.30, 1.47 0.314 -- -- --
DBO 3 485 vs. 367 0 0.825 Fixed 0.74 0.50, 1.12 0.152 0.602 1 0.603
Stent dysfunction rate Total 6 464 vs. 437 38.6 0.149 Random 0.58 0.43, 0.8 0.001 0.188 0.26 0.311
HCC 2 145 vs. 53 0 0.319 Random 0.48 0.35, 0.67 < 0.001 -- -- --
DBO 2 204 vs. 291 26.3 0.244 Random 0.59 0.39, 0.90 0.015 -- -- --
Morbidity Total 5 231 vs. 188 0 0.418 Fixed 0.77 0.64, 0.93 0.007 0.142 0.221 0.163
POPF Total 3 170 vs. 160 7.7 0.338 Fixed 0.65 0.45, 0.92 0.016 0.602 1 0.536

HCC hilar cholangiocarcinoma; DBO distant biliary obstruction; POPF postoperative pancreatic fistula; No.number of; RR risk ratio; WMD weighted mean difference; CI confidence interval

*P value

**P value (continuity corrected)

--Not applicable